Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms

Neuroendocrine neoplasms (NENs) are heterogeneous neoplasms which arise from neuroendocrine cells that are distributed widely throughout the body. Although heterogenous, many of them share their ability to overexpress somatostatin receptors (SSTR) on their cell surface. Due to this, SSTR and somatostatin have been a large subject of interest in the discovery of potential biomarkers and treatment options for the disease. The aim of this review is to describe the molecular characteristics of somatostatin and somatostatin receptors and its application in diagnosis and therapy on patients with NENs as well as the use in the near future of somatostatin antagonists.

• Publication year

  2021

• Venue

  Biomedicines

• Publication date

  2021-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/biomedicines9121810PMID 34944626PMCID 8699000
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”

  2021cited by this paper
• Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results.

  2021influential reference
• Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors.

  2021cited by this paper
• Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

  2020cited by this paper
• Somatostatin Analogs in Clinical Practice: A Review

  2020cited by this paper
• Analysis of Unusual Adverse Effects After Radium-223 Dichloride 
Administration

  2020cited by this paper
• Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2020cited by this paper
• Predictive Value of 99MTC-hynic-toc Scintigraphy in Lung Neuroendocrine Tumor Diagnosis

  2019cited by this paper
• 99mTc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung (and in other Malignant and Benign Pulmonary Diseases)

  2019cited by this paper
• The next generation of peptide receptor radionuclide therapy.

  2019cited by this paper
• Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future

  2019cited by this paper
• Role of Combined [68Ga]Ga-DOTA-SST Analogues and [18F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review

  2019cited by this paper
• Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms

  2019influential reference
• Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States.

  2019cited by this paper
• Management of carcinoid syndrome: a systematic review and meta-analysis.

  2019cited by this paper
• Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease

  2018cited by this paper
• SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018)

  2018cited by this paper
• Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial

  2018cited by this paper
• Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting

  2018cited by this paper
• International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature

  2018cited by this paper
• Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients

  2018cited by this paper
• Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms

  2018cited by this paper
• Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies

  2018cited by this paper
• The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?

  2018cited by this paper
• The Impact of Somatostatin Receptor–Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis

  2017cited by this paper
• Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

  2017cited by this paper
• Somatostatin Receptor Antagonists for Imaging and Therapy

  2017cited by this paper
• A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

  2017cited by this paper
• Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment

  2017cited by this paper
• Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications

  2017cited by this paper
• Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review

  2017cited by this paper
• Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors

  2017cited by this paper
• Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.

  2017cited by this paper
• Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors

  2017influential reference
• Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study

  2016cited by this paper
• ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors

  2016cited by this paper
• Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors

  2016cited by this paper
• Limitations and pitfalls of 99mTc-EDDA/HYNIC-TOC (Tektrotyd) scintigraphy.

  2016cited by this paper
• Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study

  2016cited by this paper
• ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas

  2016cited by this paper
• Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management

  2016cited by this paper
• Clinical application of SPECT-CT with 99mTc-Tektrotyd in bronchial and thymic neuroendocrine tumors (NETs).

  2016cited by this paper
• Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer.

  2016cited by this paper
• 99mTc-HYNIC-TOC increased uptake can mimic malignancy in the pancreas uncinate process at somatostatin receptor SPECT/CT

  2016cited by this paper
• The role of baseline Ga-68 DOTATATE positron emission tomography/computed tomography in the prediction of response to fixed-dose peptide receptor radionuclide therapy with Lu-177 DOTATATE.

  2016cited by this paper
• Evaluation of neuroendocrine tumors with 99mTc-EDDA/HYNIC TOC.

  2016cited by this paper
• Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models

  2016influential reference
• Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors

  2016cited by this paper
• ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms

  2016cited by this paper
• International Union of Basic and Clinical Pharmacology. XCIII. The Parathyroid Hormone Receptors—Family B G Protein–Coupled Receptors

  2015cited by this paper
• The efficacy of 177Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis

  2015cited by this paper
• Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.

  2015cited by this paper
• The Expanding Role of Somatostatin Analogs in Gastroenteropancreatic and Lung Neuroendocrine Tumors

  2015cited by this paper
• Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine

  2015cited by this paper
• GEP-NETS update: functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs).

  2014cited by this paper
• Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor–Expressing Neuroendocrine Tumors: The First US Phase 2 Experience

  2014cited by this paper
• Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study

  2014cited by this paper
• Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.

  2014cited by this paper
• GEP-NETS update: functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs).

  2014cited by this paper
• 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study

  2014cited by this paper
• Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours

  2014cited by this paper
• 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience

  2014cited by this paper
• The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

  2013cited by this paper
• A review of the use of somatostatin analogs in oncology

  2013cited by this paper
• Treatment with the Radiolabelled Somatostatin Analog 177Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

  2013cited by this paper
• Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis

  2013cited by this paper
• Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

  2013cited by this paper
• Somatostatin receptors: from signaling to clinical practice.

  2013cited by this paper
• Comparison of Response Evaluation in Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors After Treatment with [177Lu-DOTA0,Tyr3]Octreotate

  2013cited by this paper
• Tumores neuroendocrinos gastroenteropancreáticos Tratamiento farmacológico de los tumores neuroendocrinos gastroenteropancreáticos: análogos de somatostatina

  2013cited by this paper
• First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible

  2011cited by this paper
• Radiopeptide Imaging and Therapy in Europe

  2011cited by this paper
• Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study

  2011cited by this paper
• PET of Somatostatin Receptor–Positive Tumors Using 64Cu- and 68Ga-Somatostatin Antagonists: The Chelate Makes the Difference

  2011cited by this paper
• [177Lu-DOTA0-Tyr3]-Octreotate Treatment in Patients with Disseminated Gastroenteropancreatic Neuroendocrine Tumors: The Value of Measuring Absorbed Dose to the Kidney

  2010cited by this paper
• Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals.

  2010cited by this paper
• Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1 – molecular pathways

  2010cited by this paper
• Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

  2009cited by this paper
• One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

  2008cited by this paper
• Function and expression of somatostatin receptors of the endocrine pancreas.

  2008cited by this paper
• Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

  2008cited by this paper
• Treatment of gastroenteropancreatic neuroendocrine tumors

  2007cited by this paper
• Neuroendocrine tumors. Biotherapy.

  2007cited by this paper
• Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors

  2006cited by this paper
• [177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients

  2001cited by this paper
• [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients.

  2001cited by this paper
• The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors

  2000cited by this paper
• Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.

  1999cited by this paper
• Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.

  1996cited by this paper
• Identification and characterization of novel somatostatin antagonists.

  1996cited by this paper
• Gastroenteropancreatic endocrine tumors: Effect of Sandostatin® on tumor growth

  1992cited by this paper
• [Neuroendocrine tumors].

  1992cited by this paper
• Gastroenteropancreatic endocrine tumors: effect of Sandostatin on tumor growth. The German Sandostatin Study Group.

  1992cited by this paper
• Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin.

  1989cited by this paper
• Sequence of the human somatostatin I gene.

  1984influential reference

• “Cold” Somatostatin Analogs in Neuroendocrine Neoplasms: Decoding Mechanisms, Overcoming Resistance, and Shaping the Future of Therapy

  2025cites this paper
• Synthesis, preclinical evaluation, and clinical translation of [68Ga]Ga-Asp2-JR11, a SSTR2 antagonist for PET imaging of neuroendocrine neoplasms

  2025cites this paper
• Assessment of quantitative accuracy of SPECT/CT in dosimetric studies for 177Lu therapeutic radionuclide

  2025cites this paper
• CXCR4: From Signaling to Clinical Applications in Neuroendocrine Neoplasms

  2024cites this paper
• Carrier systems of radiopharmaceuticals and the application in cancer therapy

  2024cites this paper
• Surgical Management and Long-Term Evaluation of Pancreatic Neuroendocrine Tumors.

  2024cites this paper
• Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study

  2024cites this paper
• Radiation Safety Assessment of 177Lu-DOTATATE Intra-arterial Peptide Receptor Therapy (PRRT)

  2024cites this paper
• Comparison of scintigraphy with 123I-MIBG and 99mTc-tectrotyde in patients with tumors of a neurogenic nature

  2024cites this paper
• Immunohistochemical somatostatin receptor expression in insulinomas

  2023influential citation
• Somatostatin plus Ulinastatin in the Treatment of Severe Acute Pancreatitis and Its Effect on Serum Cytokine Levels

  2022cites this paper
• 64Cu-DOTATATE, the growing signal for PET imaging of vascular inflammation?

  2022cites this paper
• The New Radiolabeled Peptide 99mTcEDDA/HYNIC-TOC: Is It a Feasible Choice for Diagnosing Gastroenteropancreatic NETs?

  2022cites this paper
• Somatostatin receptor ligands suppressed proliferation and lipogenesis in 3T3‐L1 preadipocytes

  2022cites this paper